Etanercept improved primary biliary cirrhosis associated with rheumatoid arthritis.
Atsushi
A
Ogata
Fumitaka
F
Terabe
Kaori
K
Nakanishi
Mari
M
Kawai
Yusuke
Y
Kuwahara
Toru
T
Hirano
Jyunsuke
J
Arimitsu
Keisuke
K
Hagihara
Yoshihito
Y
Shima
Masashi
M
Narazaki
Toshio
T
Tanaka
Ichiro
I
Kawase
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D003545:Cysteine / Q000031:analogs & derivatives / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D008105:Liver Cirrhosis, Biliary / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D011239:Prednisolone / Q000627:therapeutic use; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D016896:Treatment Outcome; D028761:Withholding Treatment
D000894:Anti-Inflammatory Agents, Non-Steroidal; D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D011239:Prednisolone; D003545:Cysteine; D000068800:Etanercept; C026535:bucillamine; D008727:Methotrexate